Lasting treatment effects in a postmarketing surveillance study of prolonged-release melatonin

International Clinical Psychopharmacology

Volumn 30, Issue 1, 2015, Pages 36-42

  Hajak, Göran ^a,b   Lemme, Kathrin ^c   Zisapel, Nava ^d,e  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b Social Foundation Bamberg   (Germany)

^c Lundbeck GmbH   (Germany)

^d NEURIM PHARMACEUTICALS LTD   (Israel)

^e TEL AVIV UNIVERSITY   (Israel)

Author keywords

Hypnotics; Prolonged release melatonin; Rebound insomnia; Withdrawal symptoms

Indexed keywords

BENZODIAZEPINE DERIVATIVE; MELATONIN; ZOLPIDEM; ZOPICLONE; DELAYED RELEASE FORMULATION; HYPNOTIC SEDATIVE AGENT;

ADULT; ALERTNESS; ARTICLE; BEDTIME DOSAGE; COHORT ANALYSIS; DIZZINESS; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG RELEASE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GERMANY; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; MENTAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; POSTMARKETING SURVEILLANCE; PRESCRIPTION; PRIMARY INSOMNIA; PROLONGED DRUG RELEASE; PROSPECTIVE STUDY; REBOUND; RESTLESSNESS; SLEEP QUALITY; SLEEP WAKING CYCLE; TREATMENT DURATION; VOMITING; AGED; DELAYED RELEASE FORMULATION; DRUG EFFECTS; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SAFETY; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; SEVERITY OF ILLNESS INDEX; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; TIME; TREATMENT OUTCOME; WAKEFULNESS;

AGED; DELAYED-ACTION PREPARATIONS; FEMALE; GERMANY; HUMANS; HYPNOTICS AND SEDATIVES; MALE; MELATONIN; MIDDLE AGED; PATIENT SAFETY; PRODUCT SURVEILLANCE, POSTMARKETING; PROSPECTIVE STUDIES; RECURRENCE; RISK ASSESSMENT; RISK FACTORS; SEVERITY OF ILLNESS INDEX; SLEEP; SLEEP INITIATION AND MAINTENANCE DISORDERS; TIME FACTORS; TREATMENT OUTCOME; WAKEFULNESS;

EID: 84918789318     PISSN: 02681315     EISSN: 14735857     Source Type: Journal    
DOI: 10.1097/YIC.0000000000000046     Document Type: Article

References (21)

1. Czeisler C.A.,Dumont M,Duffy JF,Steinberg JD,Richardson GS,Brown EN,et al., 1992, Association of sleep-wake habits in older people with changes i n output of circadian pacemaker, Lancet, 340, 933-936.
2. Garfinkel D, Laudon M, Nof D, Zisapel N (1995). Improvement of sleep quality in elderly people by controlled-release melatonin. Lancet 346:541-544.
3. Grossman E, Laudon M, Yalcin R, Zengil H, Peleg E, Sharabi Y, et al. (2006). Melatonin reduces night blood pressure in patients with nocturnal hypertension. Am J Med 119:898- 902.
4. Hajak G, Bandelow B (1998). Safety and tolerance of zolpidem in the treatment of disturbed sleep: a post-marketing surveillance of 16 944 cases. Int Clin Psychopharmacol 13:157-167.
5. Hajak G , Clarenbach P, Fischer W, Haase W, Rü ther E (1994). Zopiclone improves sleep quality and daytime well-being in insomniac patients: comparison with triazolam, flunitrazepam and placebo. Int Clin Psychopharmacol 9:251-261.
6. Hajak G, Clarenbach P, Fischer W, Rodenbeck A, Bandelow B, Broocks A, Rüther E (1998). Rebound insomnia after hypnotic withdrawal in insomniac outpatients. Eur Arch Psychiatry Clin Neurosci 248:148-156.
7. Hofman MA, Swaab DF (1994). Alterations in circadian rhythmicity of the vasopressin-producing neurons of the human suprachiasmatic nucleus (SCN) with aging. Brain Res 651:134-142.
8. Lemoine P, Nir T, Laudon M, Zisapel N (2007). Prolonged-release melatonin improves sleep quality and morning alertness in insomnia patients aged 55 years and older and has no withdrawal effects. J Sleep Res 16:372-380.
9. Lemoine P, Garfinkel D, Laudon M, Nir T, Zisapel N (2011). Prolonged-release melatonin for insomnia-an open-label long-term study of efficacy, safety, and withdrawal. Ther Clin Risk Manag 7:30 1-311.
10. Lewy AJ, Emens JS, Bernert RA, Lefler BJ (2004). Eventual entrainment of the human circadian pacemaker by melatonin is independent of the circadian phase of treatment initiation: clinical implications. J Bio l Rhythms 19:68-75.
11. Lockley SW, Skene DJ, James K, Thapan K, Wright J, Arendt J (2000). Melatonin administration can entrain the free-running circadian system of blind subjects. J Endocrinol 164:R1-R6.
12. Luthringer R, Muzet M, Zisapel N, Staner L (2009). The effect of prolongedrelease melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharma col 24:239-249.
13. Mirmiran M, Swaab DF, Kok JH, Hofman MA, Witting W, Van Gool WA (1992). Circadian rhythms and the suprachiasmatic nucleus in perinatal development, aging and Alzheimer's disease. Prog Brain Res 93:151-162, discussion 162-163.
14. Roth T, Hajak G, Ustü n TB (2001). Consensus for the pharmacological management of insomnia in the new millennium. Int J Clin Pract 55:42-52.
15. Wade A, Zisapel N, Lemoine P (2008). Prolonged-release melatonin for the treatment of insomnia: targeting quality of sleep and morning alertness. Aging Health 4:11-21.
16. Wade AG, For d I, Crawford G, McMahon AD, Nir T, Laudon M, Zisapel N (2007). Efficacy of prolonged release melatonin in insomnia patients aged 55-80 years: quality of sleep and next-day alertness outcomes. Curr Med Res Opin 23:2597-2605.
17. Wade AG, Ford I, Crawford G, McConnachie A, Nir T, Laudon M, Zisapel N (2010). Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Med 8:51.
18. Wade AG, Crawford G, Ford I, McConnachie A, Nir T, Laudon M, Zisapel N (2011). Prolonged release melaton in in the treatment of primary insomnia: evaluation of the age cut-off for short-and long-term response. Curr Med Res Opin 27:87-98.
19. Wilson SJ, Nutt DJ, Alford C, Argyropoulos SV, Baldwin DS, Bateson AN, et al. (2010). British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders. J Psychopharmacol 24:1577-1601.
20. Zisapel N (200 7). Sleep and sleep disturbances: biological basis and clinical implications. Cell Mol Life Sci 64:1174-1186.
21. Zisapel N, Tarrasch R, Laudon M (2005). The relationship between melatonin and cortisol rhythms: clinical implications of melatonin therapy. Drug Dev Res 65:119-125.